Skip to main content

Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents

MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the…
Press Releases
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
Press Releases
Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière française du microbiote
Press Releases
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
Press Releases
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

See more

Videos

Media

Media

MaaT Pharma veut lever 35 millions d’euros en Bourse

Media
MaaT Pharma s’introduit sur Euronext
Media
MaaT Pharma espère lever au moins 35 M€ en Bourse

See more